Cobra Biologics Wins Manufacturing Agreement to Produce Anaerobic Bacteria
The product, consisting of live bacteria, will be used for toxicology and clinical studies for treatment of a metabolic disorder. The disorder is a rare genetic disease leading to kidney failure and end stage renal disease.
The newly aquired Cobra facility in Matfors, Sweden, has a long standing experience in large scale microbial production and will perform both the upstream and downstream work to isolate and purify the live bacteria.
Peter Coleman, CEO of Cobra Biologics said: "We are very pleased to have been selected by this company as this underlines Cobra's extensive experience and expertise in producing microbial based products for clinical trials through to commercial supply."